Helix BioPharma says its received approval from German regulatory authorities to conduct its European Phase III efficacy trial of Topical Interferon Alpha-2b in patients with low-grade cervical lesions. The company says before it can proceed, it will to secure a strategic partner to obtain funding
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/